Table 8.
Compound/extract | Origin | Concentration /Dose | Study type | Test system | Mechanism | References |
---|---|---|---|---|---|---|
Artepillin C | Brazil | 25 μM | In vitro | 3 T3-L1 adipocytes |
Inhibition of TNF-α Down regulation of adiponectin, increase of PPAR-γ activity; inhibition of TNF-α-induced JNK signaling |
[189] |
Brazil | 500 mg/Kg, orally, 14 days | In vivo | Female Swiss mice |
Decrease of inflammatory Cells, modulation of matrix remodeling |
[190] | |
Brazil | 10 mg/Kg, single oral dose | In vivo | Male Swiss mice |
Decrease of oedema, reduction of neutrophils number, decrease of prostaglandin E2 level |
[191] | |
Brazil |
10 μM 100 μM |
In vitro | RAW 264.7 cells |
Reduction in NO synthesis |
[191] | |
HEK 293 cells | Decrease of the NF-κB levels | |||||
50 μM 100 μM |
In vitro | RAW 264.7 cells |
Inhibition of IL-1β, IL-3, IL-4, IL-5, IL-9, IL-12 p40, IL-13, IL-17, TNF-α, G-CSF, GMCSF, MCP-1, MIP-1α, MIP-1β, RANTES, KC and NF-κB pathway |
[179] | ||
Brazil |
30 μg/mL 100 μg/mL |
In vitro |
Peripheral leukocytes of human blood |
Decrease cysteinyl leukotrienes and histamine | [192] | |
Propolis extract | - | 10 mg/kg | In vivo | Carrageenan rat paw oedema rat model | Reduce prostaglandins, leukotrienes and histamine | [193] |
50 and 100 mg/Kg, orally, 7 days | In vivo | Carrageenin paw edema rat model | Inhibitory effect on granuloma and exudate formation | [194] | ||
EPE with CAPE | 100–600 mg/Kg, 35 days | In vivo | Male Wistar rat model | Inhibit carrageenin oedema, carrageenin pleurisy and adjuvant arthritis | [195] | |
Propolis extracts | Cameroon | 30 μg/mL | In vitro | THP-1-derived macrophage cells | Inhibits pro-inflammatory IL-1β, TNF-α and IL-6, increase IL-10 and inhibition of purine nucleoside phosphorylase | [181] |
Neovestitol and vestitol | Brazil | 10 mg/Kg | In vivo | Male Balb/c mice | Neutrophil migration | [197] |
Bulgarian Propolis | Bulgary | ID50 = 2.5 0.4 mgkg-1 | Swiss male mice | [165] | ||
Apigenin | 50 mg/Kg, intraperitoneally, 30 days | In vivo | LPS- induced Male mice | Inhibit inflammatory cytokines, ERK1/2, NF-kB activation, and neutrophill migration | [204, 205] | |
Galangin | 50 μM | In vitro | RAW 264.7 murine macrophages | Inhibit inflammatory cytokines IL-1β and IL-6, and proinflammatory genes, such as iNOS, ERK1/2, NFkB p65 activation, and neutrophill migration | [203, 206] | |
pinocembrin | 20 or 50 mg/Kg ip | In vitro | RAW macrophage cells | Modulate the production of TNF-α, IL-1β, IL-6 and IL-10 via inhibiting the phosphorylation of IκBα, ERK1/2, JNK and p38MAPK | [212] | |
Formononetin | 10 mg/Kg, orally | In vivo | Carrageenan-induced hindpaw oedema rat model | Inhibition of leukocyte migration and activation of NF-κB | [168] | |
HERP | 10 and 30 mg/Kg, orally | |||||
Formononetin | 10 mg/Kg | In vitro | INS-1 rat insulinoma cell line | Prevent IL-1β and cytokine-induced apoptotic signaling, reducethe Bax/Bcl-2 ratio and caspase-3 activity; activateNF-κB, decease NO release | [210] | |
Neovestitol and vestitol | 10 mg/Kg | In vivo | LPS mice model | Inhibition of neutrophil migration, rolling and adhesion; inhibition of CXCL1/KC and CXCL2/MIP2 levels and neutrophil chemotaxis via blocking calcium influx | [198, 199] | |
Isoliquiritigenin | 10 mg/mL | In vitro | Human primary endothelial cells | Inhibit adhesion of neutrophil, ICAM-1, VCAM1,E-selectin and TNF-α expression, translocation of the p65 subunit of NF-κB by blocking the phosphorylation and subsequent degradation of IκBα | [213] | |
Daidzein | 2, 4, 8 mg/Kg, i.p | In vivo | Adult male Sprague–Dawley rats model | Inhibited macrophages and neutrophils infiltration, attenuated MPO activity, inhibited TLR4,MyD88 protein and NF-κB activation | [214] | |
Chinese propolis extract | China | 15 μg/mL | In vitro | RAW 264.7 cells | Inhibit the production of NO, IL-1β, and IL-6; suppress the phosphorylation of IκBα and AP-1; block the activation of NF-κB in TNF-α-stimulated HEK | [8] |
Senegalese propolis | Senegal | 30 μg/mL | In vitro | J774.1 cells | Inhibited iNOS | [216] |
EE | China | 25 and 100 mg/Kg, orally, 3 days | In vivo | RAW 264.7 cells/endotoxemic mice | Suppress the secretion of LPS-stimulated inflammatory cytokines, such as IL-6, IL-10, MCP-1, TNF-α and IL-12p70 production | [447] |
Propolis, coumaric and cinnamic acids | 50 and 100 mg/well | In vivo/ vitro | Male BALB/c mice/ Peritoneal macrophages | Inhibited IL-10 and IL-6 | [180] | |
Propolis extract | 10 μg/mL | In vitro | RAW 264.7 mouse macrophage cells | Inhibition of IL-1β, IL-6 and COX-2 mRNA expression | [211] | |
2-Acetyl-1-coumaroyl-3-cinnamoylglycerol, ( +)-2-acetyl-1-feruloyl-3-cinnamoylglycerol, ( −)-2-acetyl-1-feruloyl-3-cinnamoylglycerol, 2-acetyl-1,3-dicinnamoylglycerol and ( −)-2-acetyl-1-(E)-feruloyl-3-(3″(ζ),16″)-dihydroxy-palmitoylglycerol | 10 and 100 μM | In vitro | Lipopolysaccharide (LPS)-stimulated RAW 264.7 mouse macrophage cells | Inhibitory effects on interleukin IL-1β, IL-6, and COX-2 | [215] | |
3,3-Dimethylallyl caffeate in mixture with isopent-3-enyl caffeate | IC50 = 0.49 μM | In vivo | Ear edema test in mice | Anti-inflammatory activity | [218] | |
Arachic acid ethyl ester | 50.0 mg/Kg | In vivo | Carrageenan-induced paw edema, xylene-induced ear edema mice | Anti-inflammatory effect | [167] | |
Polyphenol-rich propolis extracts | 100 mg of CPPE/Kg | In vitro | Lipopolysaccharide (LPS)-challenged mice/HEK 293 T cells | Suppressed NF-κB activation via inhibiting the ubiquitination of TRAF6; inhibitory effects on IκBα phosphorylation and p65 nuclear translocation; lowered serum IL-6, MCP-1, IFN-γ, TNF-α and IL-12p70 | [208] | |
2-Hydroxy-8-prenylbiochanin A | IC50 = 23.3 µg/mL | In vitro | Lipopolysaccharide (LPS) stimulated J774.2 mouse macrophages | NO inhibition | [219] | |
β-Amyrine acetate | IC50 = 4.3 µg/mL | ROS inhibition | ||||
Lupeol acetate | IC50 = 1.1 µg/mL | |||||
South Brazilian organic propolis | Brazil | 0.1, 1, and 10 μg/mL | In vitro | RAW 264.7 macrophages | Decreased NF-kB activation and TNF-α release | [207] |
3′,4′-Dihydroxy-4-methoxydalbergione, 4-methoxydalbergion, cearoin, and chrysin | Nepal | 30 μg/mL | In vitro | Bone marrow-derived mast cells (BMMC) and cell cultures | Inhibited IL-33-induced mRNA expression of inflammatory genes including IL-6, TNFα and IL-13 and activation of NF-κB | [182] |
WE | 50 mg/kg, i.p | In vivo | Male Wistar albino rats | Reduced ciliary body NF-κB/p65 immunoreactivity and AH levels of HIF-1α and TNF-α | [201] | |
EE | 50 μL | In vitro | Hyaluronidase assay | Inhibited the hyaluronidase enzyme | [107] | |
Brazilian organic propolis | Brazil | 10 μg/mL | In vivo | C57BL/J6 SPF male mice | Reduced NF-κB activation, TNF-α release, and neutrophil migration | [448] |
EE | 1 mg/Kg | In vivo | Carrageenan-induced paw oedema in rats model | Decreased PGE2 and NO levels, inhibited the IL-6 increase | [217] | |
Daidzein, formononetin Aand biochanin A | 4.68 μg/mL, 31.81 μg/mL, 9.58 μg/mL | In vivo | Adult male Wistar rats | Anti-inflammatory | [209] | |
Luteolin, galangin, quercetin | 0.5 mg | In vivo | Croton oil-induced oedema in rats | Inhibited IL-1β and TNF-α | [202] | |
Lebanese propolis EE | Lebanon | 30 μg/mL | In vitro | LPS-activated RAW monocytes | Inhibited COX-2 and iNOS protein expression, as well as PGE2 and NO release | [222] |
Malaysian propolis | Malaysia | 300 mg/kg b.w | In vivo | Male Sprague Dawley rats | Reduced malondialdehyde, NFkB (p65), TNF-α, IL-1β | [221] |
CAPE | 30 mg/kg | In vivo | High-fat diet-induced obesity in mice | Reduced the induction of the inflammatory pathway, c-jun-N-terminal kinase, NF-κB, COX-2 expression | [186] | |
100 and 200 mM | In vitro | Human middle ear epithelial cells | Inhibited upregulation of TNF-α and COX-2 | [185] | ||
2.8 × 10–4–2.8 µgmL– | In vitro | Murine monocyte/macrophage J774 cell line | Inhibited COX-1 and COX-2 | [184] | ||
30 mg/kg | In vivo | Gy gamma whole-body irradiation of rats | Decreased IL‐6R, IL‐6, IL‐8, enhanced IL10, suppressed cytokine signaling-3, | [223] | ||
Caffeic acid | 10 μg/mL | In vitro | Raw 264.7 macrophages | Inhibited NO production, p38 MAPK, JNK1/2 and NF-κB | [224] | |
EEP, chrysin, galangin, kaempferol quercetin | 30 μg/mL | In vitro | J774A.1 macrophages | Suppressed both IL-1β mRNA (P < 0.02) and iNOS mRNA (P < 0.001) expression, decreased the IL-1β mRNA level and IL-1β protein concentration | [183] | |
Neovestitol | 0.22 µM | In vitro | RAW264.7 murine macrophages | Inhibited NO production and reduced GM-CSF, IFN-γ, IL-1β, IL-4, TNF-α and IL-6 levels, increased IL-10 production, down-regulated genes related to nitric oxide production, NF-κB, IL-1β, and TNF-α signaling pathways | [200] | |
Okinawa propolis | Japan | 200 μM | In vitro | RAW 264.7 cells | Reduced iNOS, COX-2, and PGE2 | [220] |